The Alabama Senate has approved a bill that would ban almost all abortions in the state, regardless of whether pregnancies were caused from rape or incest; Pennsylvania Attorney General Josh Shapiro has sued Purdue Pharmaceuticals over the company's role in the opioid epidemic; the Justice Department has decided the FDA can't regulate death penalty drugs.
The Alabama Senate approved legislation that would ban nearly all abortions in the state, making no exception for pregnancies resulting from rape or incest, The New York Times reported. The bill, which creates a direct challenge to Roe v Wade, would criminalize the procedure and charge physicians who perform them with a felony that could carry a sentence of up to 99 years in prison. The legislation will move to the desk of Governor Kay Ivey, who has not publicly commented about whether she will sign it.
Pennsylvania Attorney General Josh Shapiro sued Purdue Pharmaceuticals, the maker of OxyContin, over the company’s role in fueling the opioid epidemic, according to The Hill. The lawsuit accused the drug manufacturer of spreading more than 500,000 misleading messages about the product, claiming that physicians were assured patients with moderate to severe chronic pain would not become addicted to opioids, and that the drug had no maximum dosage. According to Shapiro, the company sold more than 2.9 million opioid prescriptions in Pennsylvania since May 2007.
In a legal opinion, the Justice Department said the FDA has no jurisdiction over death penalty drugs, CNN reported. In 2015, the FDA seizured 1000 vials of sodium thiopental from the Texas Department of Criminal Justice. The state of Texas sued the FDA in January 2017, asking the agency to release the drug from federal custody. In 2012, a federal court issued an injunction that required the FDA to block the importation of the drug “on the grounds that it was unapproved and misbranded.”
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More